Pacira BioSciences (PCRX) Stock: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$25.21
0.20 (0.80%)
▲
5d:
+0.36%
30d:
-5.15%
90d:
-1.48%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PCRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PCRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$40.20
Based on 11.6% avg growth
INTRINSIC VALUE TODAY
$24.96
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $25.21, which is considered fair relative to its 30-day fair value range of $24.68 to $26.06. The stock's valuation (Forward PE: 7.3) is in line with its historical norms (6.8). At these levels, the market is pricing in 2.5% annual earnings growth.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $25.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $30.00 (+19.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $25.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $30.00 (+19.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$24.68 -
$26.06
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($30.00)
- BULLISH: Expecting earnings turnaround to 2.5% growth with 6.2% revenue growth
- NEUTRAL: Bottoming setup forming (56/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$24.68 -
$26.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$23.98
Resistance Level
$25.77
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.32
Wall Street Target
$30.00
(+19.0%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
-30.0%
Profit Margin
2.0%
Valuation Premium vs History
+2.5% premium
PE vs Historical
7.3 vs 6.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.5%
(market-implied from PE analysis)
1-Year Target
$25.84
(+3%)
2-Year Target
$26.49
(+5%)
3-Year Target
$27.15
(+8%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$25.21
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 19.1%)
$118.62
(+371%)
Base:
(SPY PE: 7.3, Growth: 19.1%)
$42.58
(+69%)
Bear:
(PE: 6.2, Growth: 19.1%)
$36.20
(+44%)
📈
Valuation based on Current Earnings
Forward PE: 6.25 | Forward EPS (Implied): $4.03
Bull Case
$30.44
(+21%)
Analyst growth 15.0%, PE expands to 6.6
Base Case
$25.21
(0%)
Market implied 0.0%, PE stable at 6.3
Bear Case
$19.29
(-24%)
Severe decline -15.0%, PE contracts to 5.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 03, 2026 3:11 AM ET
Data refreshes hourly during market hours. Next update: 4:11 AM
Data refreshes hourly during market hours. Next update: 4:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Shawn Cross
SELL
12941 shares
2026-04-23
Shawn Cross
SELL
1500 shares
2026-04-22
Shawn Cross
SELL
2845 shares
2026-04-21
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
